While genetic mutations of CAFs are rare (Qiu et al., 2008), epigenetic changes in CAFs in breast cancer have been shown to increase fibroblast function and tumor growth rates when co-injected in xenograft models that have genetically stable p53 (Arandkar et al., 2018). This evidence concerns the gene TP53 and neoplasm.